Suppr超能文献

组蛋白 H3K9 甲基转移酶 SETDB1 增强侵袭伪足形成以促进肿瘤转移。

Histone H3K9 methyltransferase SETDB1 augments invadopodia formation to promote tumor metastasis.

机构信息

Department of Pharmacology & Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.

出版信息

Oncogene. 2022 Jun;41(24):3370-3380. doi: 10.1038/s41388-022-02345-3. Epub 2022 May 11.

Abstract

Non-small cell lung cancer (NSCLC) is one of leading causes of cancer-related mortality worldwide, which harbors various accumulated genetic and epigenetic abnormalities. Histone methyltransferase SETDB1 is a pivotal epigenetic regulator whose focal amplification and upregulation are commonly detected in NSCLC. However, molecular mechanisms underlying the pro-oncogenic function of SETDB1 remain poorly characterized. Here, we demonstrate that SETDB1 augments the migration and invasion capabilities of NSCLC cells by reinforcing invadopodia formation and mediated ECM degradation. At the molecular level, SETDB1 suppresses the expression of FOXA2, a crucial tumor and metastasis suppressor via coordinated epigenetic mechanisms - SETDB1 not only catalyzes histone H3K9 methylation on FOXA2 genomic locus, but also recruits DNMT3A to regulate DNA methylation on CpG island. Consequently, depletion of Setdb1 in murine lung adenocarcinoma cells completely abolished their full and spontaneous metastatic capabilities in mouse xenograft models. These findings together establish the pro-metastasis activity of SETDB1 in NSCLC and elucidate the underlying cellular and molecular mechanisms.

摘要

非小细胞肺癌(NSCLC)是全球癌症相关死亡的主要原因之一,其具有各种累积的遗传和表观遗传异常。组蛋白甲基转移酶 SETDB1 是一个关键的表观遗传调节剂,其在 NSCLC 中通常被检测到有焦点扩增和上调。然而,SETDB1 的致癌功能的分子机制仍知之甚少。在这里,我们证明 SETDB1 通过增强侵袭伪足的形成和介导细胞外基质的降解来增强 NSCLC 细胞的迁移和侵袭能力。在分子水平上,SETDB1 通过协调的表观遗传机制抑制 FOXA2 的表达,FOXA2 是一种关键的肿瘤和转移抑制因子——SETDB1 不仅催化 FOXA2 基因组位点上的组蛋白 H3K9 甲基化,还募集 DNMT3A 来调节 CpG 岛的 DNA 甲基化。因此,在小鼠肺腺癌细胞中耗尽 Setdb1 完全消除了它们在小鼠异种移植模型中的完全和自发转移能力。这些发现共同确立了 SETDB1 在 NSCLC 中的促转移活性,并阐明了潜在的细胞和分子机制。

相似文献

引用本文的文献

3
SETDB1 as a cancer target: challenges and perspectives in drug design.作为癌症靶点的SETDB1:药物设计中的挑战与前景
RSC Med Chem. 2024 Mar 19;15(5):1424-1451. doi: 10.1039/d3md00366c. eCollection 2024 May 22.

本文引用的文献

6

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验